ArticleCellular and molecular neurobiology2026
Plasma Extracellular Vesicles (EVs)-Mediated Immune Dysregulation and Chronic Inflammation in Autism Spectrum Disorder.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by repetitive behaviors, communication deficits, and frequent comorbidities. While both genetic and environmental factors contribute to ASD etiology, immune dysregulation has emerged as a potential environmental driver, suggesting a critical role of chronic inflammation in ASD pathophysiology. We previously demonstrated that ASD individuals display specific changes in plasma EV cargo which is associated with immune dysregulation. Here, we show that ASD EVs contain dysregulated cytokine profiles, including Gro-α/CXCL1, RANTES/CCL5, IFN-γ, stem cell growth factor beta (SCGF-β), and IL-15. Notably, ASD EVs enhance IFN-γ secretion from peripheral blood lymphocytes (PBLs) in direct co-cultures, which can be reversed by treatment with the anti-inflammatory agent dexamethasone (Dex). Our findings suggest that ASD EVs contribute to chronic inflammation and highlight a potential therapeutic target for ASD intervention by mitigating ASD EV-induced chronic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.